Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

58.54 -0.89 (-1.50%)
Official Closing Price Updated: 7:00 PM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
88 89 Next >
News headline image
Why Bristol Myers Squibb Stock Is Sinking Today ↗
Investors didn't like the biopharmaceutical company's updated guidance. 
Via The Motley Fool
News headline image
BMY Stock Earnings: Bristol-Myers Squibb Beats EPS, Beats Revenue for Q1 2024 ↗
BMY stock results show that Bristol-Myers Squibb beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Bristol-Myers Squibb Layoffs 2024: What to Know About the Latest BMY Job Cuts ↗
Bristol-Myers Squibb layoffs will see the company reduce its headcount by 6% as part of an effort to reduce expenses in 2024. 
Via InvestorPlace
Topics Workforce
News headline image
Bristol Myers Squibb (BMY) Q1 2024 Earnings Call Transcript ↗
BMY earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Is Bristol Myers Squibb Stock a Millionaire Maker? ↗
Bristol Myers Squibb faces some challenges, but there could be light at the end of the tunnel for long-term investors. 
Via The Motley Fool
News headline image
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market ↗
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate. 
Via Investor's Business Daily
News headline image
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics ↗
 
Via Benzinga
News headline image
Market Whales and Their Recent Bets on BMY Options ↗
 
Via Benzinga
News headline image
Peering Into Bristol-Myers Squibb's Recent Short Interest ↗
 
Via Benzinga
News headline image
AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags ↗
AstraZeneca soundly topped analyst views while Sanofi narrowed its losses. Both stocks surged in early trade. 
Via Investor's Business Daily
News headline image
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
From Bristol Myers Squibb
Via Business Wire
News headline image
Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual Outlook ↗
Discover Novartis' Q1 EPS soars 17% to $1.80, surpassing estimates. Sales hit $11.83B, up 10%. Entresto sales surge 36%, Cosentyx up 25%. CEO Vas Narasimhan bullish on mid & long-term growth. 
Via Benzinga
News headline image
5 Crash-Proof Stocks to Buy Immediately ↗
We may not be headed to a full-blown crisis, but savvy investors should protect their portfolios now with these crash-proof stocks. 
Via InvestorPlace
News headline image
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
From Bristol Myers Squibb
Via Business Wire
News headline image
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst ↗
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platforms, Inc.’s (NASDAQ:META) 
Via Benzinga
News headline image
3 High-Yielding Dividend Stocks That Are Trading at Dirt-Cheap Valuations ↗
These stocks pay between 3.2% and 6.7% in dividends. 
Via The Motley Fool
News headline image
This Is What Whales Are Betting On Bristol-Myers Squibb ↗
 
Via Benzinga
News headline image
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week ↗
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1. 
Via Benzinga
News headline image
These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher? ↗
Small-cap stocks have been the market laggards but these standouts showed how to beat even top-tier tech names at their own game. 
Via InvestorPlace
News headline image
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies ↗
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel 
Via Benzinga
News headline image
Got $500? 3 Healthcare Stocks to Buy and Hold Forever ↗
Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk. 
Via The Motley Fool
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
Via AB Newswire
Topics Economy
News headline image
3 Undervalued Dividend Stocks to Buy Now to Beat the S&P 500 ↗
If you want to outperform the S&P 500, consider these undervalued dividend stocks for juicy yields and high total return potential. 
Via InvestorPlace
Topics Stocks
News headline image
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years ↗
These income stocks look like good options at current levels. 
Via The Motley Fool
News headline image
3 Pharma Stocks That Are Money-Printing Machines in 2024 ↗
The economy, and pharma industry, are projected to grow massively. You should invest in these top three pharma stocks. 
Via InvestorPlace
Topics Economy
News headline image
Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug ↗
The company was testing a potential treatment for schizophrenia in rabbits, but found a notable side effect. 
Via Investor's Business Daily
News headline image
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF? ↗
Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard S&P 500 ETF? 
Via The Motley Fool
Topics Stocks
News headline image
Better Growth Play: Merck or The Vanguard Growth Index Fund? ↗
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund? 
Via The Motley Fool
News headline image
Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom ↗
The latest Phase 1 trial results of Agenus' botensilimab and balstilimab (BOT/BAL) combination therapy for metastatic CRC showcase promising clinical activity. 
Via Benzinga
News headline image
Wall Street Favorites: 3 Warren Buffett Stocks With Strong Buy Ratings for April 2024 ↗
If you’re wondering where to invest in a stock picker's market, these three Warren Buffett stocks are a good place to start. 
Via InvestorPlace
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
88 89 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.